JP2019500320A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500320A5
JP2019500320A5 JP2018522569A JP2018522569A JP2019500320A5 JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5 JP 2018522569 A JP2018522569 A JP 2018522569A JP 2018522569 A JP2018522569 A JP 2018522569A JP 2019500320 A5 JP2019500320 A5 JP 2019500320A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
rsv
protein
virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522569A
Other languages
English (en)
Japanese (ja)
Other versions
JP7311872B2 (ja
JP2019500320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/058976 external-priority patent/WO2017075125A1/en
Publication of JP2019500320A publication Critical patent/JP2019500320A/ja
Publication of JP2019500320A5 publication Critical patent/JP2019500320A5/ja
Priority to JP2023065428A priority Critical patent/JP2023100654A/ja
Application granted granted Critical
Publication of JP7311872B2 publication Critical patent/JP7311872B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522569A 2015-10-29 2016-10-27 キメラrsv、免疫原性組成物、及び使用方法 Active JP7311872B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065428A JP2023100654A (ja) 2015-10-29 2023-04-13 キメラrsv、免疫原性組成物、及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562247962P 2015-10-29 2015-10-29
US62/247,962 2015-10-29
US201662334547P 2016-05-11 2016-05-11
US62/334,547 2016-05-11
PCT/US2016/058976 WO2017075125A1 (en) 2015-10-29 2016-10-27 Chimeric RSV, Immunogenic Compositions, and Methods of Use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065428A Division JP2023100654A (ja) 2015-10-29 2023-04-13 キメラrsv、免疫原性組成物、及び使用方法

Publications (3)

Publication Number Publication Date
JP2019500320A JP2019500320A (ja) 2019-01-10
JP2019500320A5 true JP2019500320A5 (enExample) 2019-12-05
JP7311872B2 JP7311872B2 (ja) 2023-07-20

Family

ID=58630734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018522569A Active JP7311872B2 (ja) 2015-10-29 2016-10-27 キメラrsv、免疫原性組成物、及び使用方法
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラrsv、免疫原性組成物、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065428A Pending JP2023100654A (ja) 2015-10-29 2023-04-13 キメラrsv、免疫原性組成物、及び使用方法

Country Status (10)

Country Link
US (2) US11235050B2 (enExample)
EP (1) EP3368547A4 (enExample)
JP (2) JP7311872B2 (enExample)
KR (1) KR20180085730A (enExample)
CN (1) CN108602858A (enExample)
BR (1) BR112018008708A2 (enExample)
CA (1) CA3003726A1 (enExample)
MX (1) MX2018005462A (enExample)
SG (1) SG11201803581VA (enExample)
WO (1) WO2017075125A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113322264B (zh) 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN113164583A (zh) * 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
CN113631187A (zh) 2019-02-11 2021-11-09 埃默里大学 嵌合RSV和hMPV F蛋白、免疫原性组合物和使用方法
MX2023011784A (es) * 2021-04-08 2023-10-11 Codagenix Inc Metodo para provocar una respuesta inmunitaria contra virus sincitial respiratorio.
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AT401526B (de) 1993-02-10 1996-09-25 Scheirer Winfried Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US6713066B1 (en) 1996-07-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6923971B2 (en) 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US6214805B1 (en) 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6074859A (en) 1997-07-08 2000-06-13 Kikkoman Corporation Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US20020018780A1 (en) * 2000-05-25 2002-02-14 Scott Koenig Epitope-based vaccine for respiratory syncytial virus F-protein
ATE469170T1 (de) 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
HUE032898T2 (hu) 2003-12-24 2017-11-28 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport Légúti óriássejtes vírus transz komplementált genomi hiányossággal
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
CN103476425B (zh) 2007-03-30 2015-07-15 纽约州州立大学研究基金会 用于疫苗的减毒病毒
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
AU2009311287C1 (en) 2008-11-05 2015-02-19 Merck Sharp & Dohme Corp. Live, attentuated respiratory syncytial virus
KR101691574B1 (ko) 2008-12-09 2017-01-02 노바백스, 인코포레이티드 변형 rsv f 단백질 및 이들의 사용 방법
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
WO2011046925A1 (en) 2009-10-12 2011-04-21 Technovax, Inc. Respiratory syncytial virus (rsv) virus-like particles (vlps)
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
CN103842374A (zh) 2011-05-13 2014-06-04 诺华股份有限公司 融合前的rsv f抗原
CA2840982C (en) 2011-07-06 2022-06-07 Vira BITKO Human respiratory syncytial virus vaccine
US8816081B2 (en) 2012-08-06 2014-08-26 Basf Se Boron containing perylene monoimides, a process for their production, their use as building blocks for the production of perylene monoimide derivatives, monoimide derivatives and their use in dye-sensitized solar cells
ES2952387T3 (es) 2013-02-08 2023-10-31 Us Health Atenuación del virus respiratorio sincitial humano mediante la desoptimización de pares de codones a escala genómica
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN113322264B (zh) * 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions

Similar Documents

Publication Publication Date Title
US11389523B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
JP6990814B2 (ja) アヒル腸炎ウイルス及びその使用
JP2017503482A5 (enExample)
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
CN108368488B (zh) 鸭肠炎病毒及其用途
CN104353070B (zh) 一种鸡传染性支气管炎病毒的基因工程亚单位疫苗及其制备方法
CN104293741A (zh) 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用
US20230310581A1 (en) A live attenuated measles virus vectored vaccine for sars-cov-2
JP2021500876A (ja) 複数の異種抗原をコードする組換え非病原性マレック病ウイルス構築物
WO2020215350A1 (zh) 禽流感与禽腺病毒4型二联基因工程亚单位疫苗及其制备方法
ZA200509187B (en) DNA vaccine expressing HA 1 of equine-2 influenza virus
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
CN104031889A (zh) 表达传染性法氏囊病毒vp2蛋白的重组火鸡疱疹病毒疫苗及应用
JP2016513471A (ja) サイレント変異を有する組換えrsv、ワクチン、およびそれに関連する方法
Ying et al. Construction and immunological characterization of CD40L or GM-CSF incorporated Hantaan virus like particle
WO2005054451A1 (ja) 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
WO2015049633A1 (es) FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADJUVANTE, APTA PARA SU USO FARMACEUTICO.
CN113430178B (zh) 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
CN103316357B (zh) 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法
JP2025502236A (ja) インフルエンザウイルスの弱体化方法および弱体化インフルエンザウイルス株、ならびにその使用
Mu et al. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン